Esperion Appoints Ben Halladay Chief Financial Officer
November 16 2022 - 4:00PM
Esperion (NASDAQ: ESPR) today announced that Ben Halladay, MBA, has
been promoted to the role of Chief Financial Officer (CFO) from his
prior position of Senior Director, Financial Planning and Analysis,
effective as of today. He will serve as a member of the executive
management team and report to Sheldon Koenig, President and Chief
Executive Officer.
“We are thrilled to have Ben take on this expanded role on the
Esperion leadership team with his promotion to CFO,” said Sheldon
Koenig, President and CEO of Esperion. “Ben has made significant
contributions since joining the company in 2020, supporting our
finance organization during a transitional period of organizational
restructuring and establishing himself as a strong and capable
leader over the past several months. I look forward to continuing
to work together during this important time for the company as we
approach the topline readout of CLEAR Outcomes, and I am confident
he will position Esperion for long-term success in his new role as
CFO.”
Mr. Halladay said, “I am excited by the opportunity to join
Esperion’s leadership team at such a pivotal time for the Company,
as we deliver value to both patients and our shareholders.”
Mr. Halladay has served as the Company’s Senior Director,
Financial Planning and Analysis since August 2022. Prior to joining
the Company in January 2020, Mr. Halladay held a variety of finance
rolls at National Oilwell Varco, BMC Software, and Pfizer and holds
his CPA license. Mr. Halladay graduated with a Bachelor of Arts
from Syracuse University and a Master in Business Administration
from Fordham Gabelli School of Business.
Esperion TherapeuticsEsperion works hard to
make our medicines easy to get, easy to take and easy to have. We
discover, develop, and commercialize innovative medicines and
combinations to lower cholesterol, especially for patients whose
needs aren’t being met by the status quo. Our entrepreneurial team
of industry leaders is inclusive, passionate, and resourceful. We
are singularly focused on managing cholesterol so you can improve
your health easily. For more information, please visit
www.esperion.com and follow us on Twitter at
www.twitter.com/EsperionInc.
Forward-Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements regarding marketing strategy and commercialization
plans, current and planned operational expenses, future operations,
commercial products, clinical development, including the timing,
designs and plans for the CLEAR Outcomes study and its results,
plans for potential future product candidates, financial condition
and outlook, including expected cash runway, and other statements
containing the words “anticipate,” “believe,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,” and
similar expressions. Any express or implied statements contained in
this press release that are not statements of historical fact may
be deemed to be forward-looking statements. Forward-looking
statements involve risks and uncertainties that could cause
Esperion’s actual results to differ significantly from those
projected, including, without limitation, the impact of the ongoing
COVID-19 pandemic on our business, revenues, results of operations
and financial condition, the net sales, profitability, and growth
of Esperion’s commercial products, clinical activities and results,
supply chain, commercial development and launch plans, and the
risks detailed in Esperion’s filings with the Securities and
Exchange Commission. Any forward-looking statements contained in
this press release speak only as of the date hereof, and Esperion
disclaims any obligation or undertaking to update or revise any
forward-looking statements contained in this press release, other
than to the extent required by law.
Contact:Esperion Corporate
Communicationscorporateteam@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024